Initial Results of a Phase I Dose-Escalation Trial of Concurrent and Maintenance Erlotinib and Reirradiation for Recurrent and New Primary Head-and-Neck Cancer
- 1 November 2010
- journal article
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 78 (4) , 1020-1025
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Randomized Trial of Postoperative Reirradiation Combined With Chemotherapy After Salvage Surgery Compared With Salvage Surgery Alone in Head and Neck CarcinomaJournal of Clinical Oncology, 2008
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck CancerNew England Journal of Medicine, 2008
- Phase II Study of Low-Dose Paclitaxel and Cisplatin in Combination With Split-Course Concomitant Twice-Daily Reirradiation in Recurrent Squamous Cell Carcinoma of the Head and Neck: Results of Radiation Therapy Oncology Group Protocol 9911Journal of Clinical Oncology, 2007
- Final report of RTOG 9610, a multi‐institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neckHead & Neck, 2007
- High Incidence of Cetuximab-Related Infusion Reactions in Tennessee and North Carolina and the Association With Atopic HistoryJournal of Clinical Oncology, 2007
- Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and NeckNew England Journal of Medicine, 2006
- Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006
- Randomized Phase III Evaluation of Cisplatin Plus Fluorouracil Versus Cisplatin Plus Paclitaxel in Advanced Head and Neck Cancer (E1395): An Intergroup Trial of the Eastern Cooperative Oncology GroupJournal of Clinical Oncology, 2005
- Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split‐course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studiesHead & Neck, 2005
- Phase III Comparison of High-Dose Paclitaxel + Cisplatin + Granulocyte Colony-Stimulating Factor Versus Low-Dose Paclitaxel + Cisplatin in Advanced Head and Neck Cancer: Eastern Cooperative Oncology Group Study E1393Journal of Clinical Oncology, 2001